Last reviewed · How we verify
controlled release carvedilol
At a glance
| Generic name | controlled release carvedilol |
|---|---|
| Also known as | Coreg CR |
| Sponsor | University of Arkansas |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Optimising Pacing Therapy, Integrated Medical Therapy, and Catheter AbLation for Atrial Fibrillation in Heart Failure Trial (PHASE4)
- Effect of Non-Selective Beta-Blockers on Outcomes in Cirrhosis Patients After Hospitalization: A Retrospective Cohort Using Target Trial Design
- Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. (PHASE4)
- A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure (PHASE3)
- Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab (PHASE2)
- Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure (PHASE4)
- COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria (PHASE3)
- Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- controlled release carvedilol CI brief — competitive landscape report
- controlled release carvedilol updates RSS · CI watch RSS
- University of Arkansas portfolio CI